Cargando…
MicroRNA-34a, Prostate Cancer Stem Cells, and Therapeutic Development
SIMPLE SUMMARY: Prostate cancer is still the most common cancer among men in the US. Current standard-of-care therapies for metastatic castration-resistant prostate cancer can offer survival benefits measured only in months. The patients eventually develop drug resistance and tumor relapse. There is...
Autores principales: | Li, Wen (Jess), Liu, Xiaozhuo, Dougherty, Emily M., Tang, Dean G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9497236/ https://www.ncbi.nlm.nih.gov/pubmed/36139695 http://dx.doi.org/10.3390/cancers14184538 |
Ejemplares similares
-
MicroRNA-34a: Potent Tumor Suppressor, Cancer Stem Cell Inhibitor, and Potential Anticancer Therapeutic
por: Li, Wen (Jess), et al.
Publicado: (2021) -
Prostate cancer as a dedifferentiated organ: androgen receptor, cancer stem cells, and cancer stemness
por: Liu, Xiaozhuo, et al.
Publicado: (2022) -
MicroRNA-34a: a potential therapeutic target in human cancer
por: Li, X J, et al.
Publicado: (2014) -
MicroRNA-34 Family in Cancers: Role, Mechanism, and Therapeutic Potential
por: Fu, Junjiang, et al.
Publicado: (2023) -
MicroRNA-34 family: a potential tumor suppressor and therapeutic candidate in cancer
por: Zhang, Lu, et al.
Publicado: (2019)